Myocardial ischemia-
reperfusion injury (MIRI) is a phenomenon that reperfusion leads to irreversible damage to the myocardium and increases mortality in acute
myocardial infarction (AMI) patients. There is no effective
drug to treat MIRI.
Tubeimoside I (TBM) is a
triterpenoid saponin purified from
Chinese traditional medicine tubeimu. In this study, 4 mg/kg TBM was given to mice intraperitoneally at 15 min after
ischemia. And TBM treatment improved postischemic cardiac function, decreased
infarct size, diminished
lactate dehydrogenase release, ameliorated oxidative stress, and reduced apoptotic index. Notably,
ischemia-reperfusion induced a significant decrease in cardiac
SIRT3 expression and activity, while TBM treatment upregulated
SIRT3's expression and activity. However, the cardioprotective effects of TBM were largely abolished by a
SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl)
pyridine (3-TYP). This suggests that
SIRT3 plays an essential role in TBM's cardioprotective effects. In vitro, TBM also protected H9c2 cells against simulated
ischemia/reperfusion (SIR) injury by attenuating oxidative stress and apoptosis, and siSIRT3 diminished its protective effects. Taken together, our results demonstrate for the first time that TBM protects against MIRI through SIRT3-dependent regulation of oxidative stress and apoptosis. TBM might be a potential
drug candidate for MIRI treatment.